Innovotech Inc. (TSX-V: IOT) has announced record revenues for the third quarter of 2025, reaching $1,267,692 with a net income of $92,945. The company's year-to-date revenue stands at $3,410,204, reflecting robust growth across multiple business segments. This financial milestone highlights the success of Innovotech's diversified portfolio, which includes antimicrobial contract research services, analytical services through its wholly-owned subsidiary Keystone Labs, and increasing product sales.
According to Craig Milne, CEO of Innovotech, the record performance is the result of deliberate investments and parallel efforts to build a foundation for continued growth. "We are pleased to see the financial performance reflecting the changes underway," Milne stated. The company has been expanding its capabilities in specialized laboratory services and biotechnology, positioning itself for sustained momentum.
Innovotech's contract research organization, Innovotech Labs Corporation, provides proprietary devices for antimicrobial testing across multiple applications, a service that has seen growing demand. Additionally, Keystone Labs Inc., a DEL-accredited laboratory serving the Canadian pharmaceutical and industrial markets, has delivered strong analytical services. The company also holds a 60% stake in NouLifeSciences Inc., which owns intellectual property related to antioxidant molecules with potential applications in cosmetics and neuropathies.
The record revenue marks a significant achievement for Innovotech, which operates in a competitive and regulated industry. The company's ability to generate net income while investing in growth initiatives signals financial discipline and operational efficiency. For investors, the quarterly results demonstrate the tangible outcomes of the company's strategic focus on expanding its service offerings and product sales.
Looking ahead, Innovotech aims to leverage its proprietary technologies and accredited labs to capture further market share. The growing demand for antimicrobial testing, driven by global health concerns and regulatory requirements, positions the company favorably. However, the company acknowledges forward-looking risks, including regulatory changes, reliance on a small number of customers, and fluctuations in operating results.
For more information about Innovotech's services, visit www.innovotech.ca and www.keystonelabs.ca.
